Despite early intervention, 20–50% of men with PCa will develop biochemical recurrence (BCR) within 10 years after initial definitive therapy, characterized by a rising serum prostatic-specific antigen (PSA) [3, 4]. The gene discussed is KLK3; the disease is posterior cortical atrophy.